Drug development involves a deep understanding of the mechanisms of action and possible side effects of each drug, and sometimes results in the identification of new and unexpected uses for drugs, termed as drug repurposing. Both in case of serendipitous observations and systematic mechanistic explorations, confirmation of new indications for a drug requires hypothesis building around relevant drug-related data, such as molecular targets involved, and patient and cellular responses. These datasets are available in public repositories, but apart from sifting through the sheer amount of data imposing computational bottleneck, a major challenge is the difficulty in selecting which databases to use from an increasingly large number of available databases. The database selection is made harder by the lack of an overview of the types of data offered in each database. In order to alleviate these problems and to guide the end user through the drug repurposing efforts, we provide here a survey of 102 of the most promising and drug-relevant databases reported to date. We summarize the target coverage and types of data available in each database and provide several examples of how multi-database exploration can facilitate drug repurposing.
Introduction
Drug repurposing/repositioning is the process of assigning indications for drugs other than the one(s) that they were originally developed for. This definition is somewhat subjective; the cases where drugs are assigned uses in different forms of a class of indications, such as, in different cancer types, which could have been expected, particularly if the mechanism of action is the same, and thus, may not be considered repurposing. Drug repositioning implies the involvement of an unexpected element and is usually distinguished from the utility extension, in which a drug is launched for different forms or stages of the same indication, sharing the same mode of action. Examples of utility extension include the approval of dasatinib for newly diagnosed chronic myeloid leukaemia (CML), having first been approved only for imatinib-relapsed CML [1] , and antiangiogenic antibody bevacizumab gaining approval first in colon cancer and later in other solid cancers. Utility extension is also known as market expansion and is a central drug development strategy for the pharmaceutical industry to ensure revenue as the average cost of developing a drug from scratch ranges from 1 to 2 billion dollars [2, 3] , while drugs granted extended uses mainly incur only the regulatory and administrative costs. Discovery of entirely new indications for drugs is also highly lucrative as several development steps can be minimized. For example, clinical trial data existing on adult individuals for the 'morning sickness' drug thalidomide contributed to its approval for multiple myeloma in 2012 at an estimated cost of only $40-80 million [4] . Another example of a profitable genuine drug repositioning is Minoxidil, which was originally developed for hypertension but was later repositioned to treat male hair loss [5] . Similarly, kinase inhibitor imatinib was developed and first approved to target BCR-ABL in CML but was later was found to be effective in targeting KIT in gastrointestinal stromal tumors (GIST) [6] .
Apart from drug repositioning and utility extension, in many cases, a distinction can be made for drug development repositioning (sometimes called drug rescue), where a drug candidate developed for a certain indication fails but ends up being used for a different indication [7] . An example of this type of repositioning is Sildenafil (Viagra), which failed to meet its primary endpoints in angina pectoris and hypertension, but instead is very successful as a medicine for erectile dysfunction [8] . Other examples of such drug repositioning include cancer drugs crizotinib, sorafenib, azacitidine and decitabine, all of which failed to reach the markets in their original indications, yet now are important tools in the treatment of other types of cancers [9] .
Underlying both traditional drug development and drug repositioning are mechanistic explanations, which depend on sufficient drug target and phenotypic annotations. Since the 1990s and onwards, rapid development in the high throughput screening technologies has created an environment for expediting the discovery process by enabling huge libraries of compounds and molecular targets to be interrogated in a short amount of time. At the same time, advances in the computational methods and availability of public databases have vastly increased the possibility to create novel models and hypotheses for drug mechanisms and to narrow down the top hits by in silico validations [10] [11] [12] [13] [14] [15] .
This has created opportunities to assess the potential for new drug uses even before the experimental testing, which has proven particularly attractive for orphan diseases, in which traditional drug development is limited [16, 17] . In the United States, drug development and clinical research for rare diseases is encouraged by fast track FDA approval and marketing protection and tax alleviations, creating a niche for drug repositioning efforts that can offset the smaller revenue expectations arising from the limited number of patients.
Public data repositories are a considerable asset to drug development, but one of the biggest challenges of elevating drug repositioning to an informed and consistent parallel alternative to primary indication-oriented drug development has been mapping of the mechanisms of action and downstream interactions of the agents [13, 18] . Several reviews have been published highlighting the tools and methodologies leading to drug repositioning. For instance, Dudley et al. [19] have published a review on computational methods for drug repositioning and classified the methodologies either as drug or diseasebased repositioning. Jin et al. [20] , have linked existing drugrepositioning methods with their integrated biological and pharmaceutical knowledge and have discussed how to customize a new drug-repositioning pipeline for specific studies. Sam et al. [21] have presented web-based tools that can aid in repositioning of the drugs. Li et al. [22] have summarized recent progress in computational drug repositioning into four parts: repositioning strategies, computational approaches, validation methods and application areas. Song et al. [23] have discussed major tools and resources that have been developed for repositioning the drugs, and Yang et al. [24] have recently provided an extensive review on the use of artificial intelligence for drug repurposing. Several databases are being developed every year to support the drug repositioning and are published in the database-related issues of the journals. For instance, Nucleic Acids Research Database Issue contains information on more than 1700 unique databases and 64 new databases [25] . However, another major challenge in drug repositioning is that the mechanistic and phenotypic data necessary to distil new purposes for the 'old' drugs are spread out over a vast and increasing number of data repositories, with data that may vary significantly in quality and reliability. In this review, we have provided a comprehensive review of such publicly available databases by placing them into four categories: chemical, biomolecular, drug-target interaction and disease databases and then further dividing each into subcategories. Furthermore, we have compared the databases using various parameters, such as the number of chemicals, genes, diseases, etc., in order to facilitate the researchers in selecting appropriate databases for specific purposes. We also highlight several new databases that have not been previously covered in any review (e.g. [10, 23] ), including: DepMap [26] , cBioPortal [27] , Probes & Drugs portal [28] , DrugComb [29] , DrugTargetCommons(DTC) [30] , DrugTargetProfiler (DTP) [31] , IDAAPM [32] , PharmacoDB [33] and DisGeNet [34] . Some of these databases can provide additional datasets and create news ways to support drug repurposing. For example, DrugComb [29] provides combination responses in terms of sensitivity and synergy measures; PharmacoDB [33] has integrated and standardized several drug sensitivity resources and DTC [30] provides a crowd sourcing platform to integrate drug target interactions. The present survey will provide readers a useful comparison on drug repurposing databases and help them to select right database for their analysis.
The rest of the manuscript is structured into three sections, starting in Section 2 by providing an overview about all the databases, including data statistics and subcategories. Section 3 further highlights the recommended databases for each subcategory based on data quality and comprehensiveness. In Section 4, we have provided representative applications of the databases and shown how these databases can be used for drug repositioning. Finally, Section 5 concludes the manuscript with key points.
Databases providing drug repositioning information
The databases covered in this research are divided into four main categories i.e. chemical, biomolecular, drug-target interaction and disease databases. The main category names are defined after the compilation of database list and assessing their scope. These categories are further divided into subcategories and explained in subsequent sections. Each main section contains a table, providing short introduction and summary statistics for the databases in terms of various parameters (e.g. number of citations, application programming interface (API), number of proteins, chemicals, diseases and protein to disease associations) falling in each of the subcategories for that section.
Several databases fall into more than one subcategory because of the multiple data types. In Figure 1 , we have highlighted only those databases that belong to more than Figure 1 . Drug repositioning databases categorized into more than one subcategory. Some subcategories are shown more than once in order to facilitate the interpretation of database relationships. one subcategory in order to highlight heterogeneity in the data types. The subcategories are color coded according to four main categories and the links are also color coded. Drug repositioning can be a complicated process that involves various steps and may require various types of data analysis and experimental validation. Figure 1 can help the researchers to select the most relevant databases, as required by their repositioning applications. In the Tables 1-4, we have listed the databases as a single main category, with the explicit acknowledgement that the databases may also belong to other categories using color-coding scheme as shown in Figure 1 . A single main or subcategory for the databases was assigned after thoroughly reading the database descriptions and analyzing data types to determine which datatype is the primary focus and main strength of a database. For example, main strength of the KEGG [35] database is the pathway information, but it also contains additional datatypes, such as drug target interactions, as shown in Figure 1 . Hence, we assigned 'Pathways' as primary subcategory for KEGG, which is listed under the main category 'biomolecular', as shown in Table 2 . Similarly, main strength of DrugBank [36] is drug target interactions data, which is clearly visible by reading its description and checking the data statistics, but it also provides clinical, drug classification, chemical structures, pathways and drug combination information. Figure 1 can be especially helpful for researchers who are interested in various datatypes or crossdatabase comparative analysis.
Chemical databases
There are 12 chemical databases, which have been further divided into four subcategories: drug combination, drug classification, chemical structures and drug omics databases. The subcategory 'Drug combination' contains databases with screening data for combinatorial therapies. Drug classification databases provide classification for the drugs based on the mechanism of action, structure similarity or other parameters. The subcategory 'Chemical Structures' contains databases with data on chemical structures. Drug omics databases contain drug response data for various cancer cell lines. The detailed information about individual databases is shown in Table 1 .
Most of the databases that fall into the chemical category do not provide application programming interface (API) i.e. no tick mark under API column in the Table 1 . The last column (Cit) shows the sum of the citations for all publications on a database and was computed on 25 May 2019, 18:00 CET. This number might increase as more and more researchers will be citing these databases, but it can give an idea about which of the databases are being mostly used. Reference information for some of the databases is missing as we could not find associated publications.
Biomolecular databases
There are 52 biomolecular databases that we have covered in this review. For a better understanding, we have divided the databases into seven subcategories: genomics, proteomics, protein classification, protein 3D structures, molecular omics, protein-protein interactions and pathways databases. Genomics databases comprise of gene visualizations, whereas proteomics databases contain protein sequences and visualizations. Protein 3D structure databases have comprehensive data on protein structures. Molecular omics databases comprise RNA or protein expression-related information. The subcategory 'protein-protein interactions' contains databases on proteinprotein interactions and protein complexes. The subcategory 'pathways' lists databases with signaling pathways and 'protein classification' comprises databases that can provide some sort of classification system for proteins or genes. More details on individual databases are shown in Table 2 , and in case the information is not available, those sections in the table are left blank and the column headers are abbreviated at the bottom of the table.
Drug-target interactions databases
We have divided this category into three subcategories: bioactivity data, drug-target binary interactions and drug-target interaction visualizations. We covered 17 databases, which contain data on either bioactivity or drug-target interactions. The subcategory 'bioactivity data' lists only those databases that report compound-target interactions in terms of dose response measurements (e.g. IC50, Kd, Ki) whereas drug-target interaction databases report quantitative data (binary interactions). The drug-target interaction visualization databases in addition to providing information on bioactivity or drug-target binary interactions also provide visualizations for interaction networks, which can be exported as figures. Databases are assessed using parameters, such as the number of compounds (C), number of targets (T), number of compound-target interactions (I), number of citations (Cit) and API, as shown in Table 3 . Citation information was computed on 25 May 2019, 18:00 CET. Table 3 contains further details and statistics on individual databases.
Disease databases
There are 19 databases in this category as shown in Table 4 . Databases under disease subcategory mostly contain diseasegene associations. The subcategory 'clinician information' contains databases that report clinical studies and disease indications while the subcategory 'side effects' represents those databases that show possible side effects of the drugs in diseased patients. The databases in disease category are represented using parameters, such as the number of compounds, proteins, diseases, protein-disease associations, API (tick-marked if data access is provided by API) and number of citations (citation information was computed on 25 May 2019, 18:00 CET).
Recommended databases in each subcategory
Tables 1-4 provide short descriptions, statistics, datatypes for subcategories and other characteristics for individual databases, but it is still difficult to select best databases from a comprehensive list of 102 databases using 4 main categories and 17 subcategories. Hence, in this section, we have tried to suggest the best database(s) for each subcategory based on statistics, quality, availability, data redundancy, features, variety of data types and database usage (based on citations).
Chemical databases
Among drug combination databases, DrugComb [29] and Drug-CombDB [37] provide qualitative drug combination responses in terms of sensitivity and synergy measures. Additionally, DrugComb also provides visualization of drug combination data for >4500 drugs; hence, we recommend DrugComb for drug combination data mining. For Drug omics, we propose GDSC [42] as it is one of the most comprehensive drug omics database with >1000 cancer cell lines and with data from >75 000 experiments. GDSC also provides API to programmatically access data and linked drug omics with molecular omics, as shown in Table 1 .
Biomolecular databases
Among genomics databases, we suggest Ensembl [47] as it is very comprehensive, focusing on >5000 species with deep curation and API access. Furthermore, it contains data for protein variants, genomic visualizations, linked pathways and molecular omics information. Among the proteomics databases, UniProt [118] could be the one choice as it integrates a wide variety of data types, such as pathways, protein-protein interactions (PPI), molecular omics, protein sequences, structures, classification and protein disease associations, as shown in Figure 1 . UniProt is quite comprehensive, focusing on ∼1 million species and also contains data on protein variants, which can be accessible using APIs (Table 2) . Among PPI databases, BioGRID [66] could be used as it contains 1.3 million nonredundant PPIs. Additionally, BioGRID has associated PPI data with drug target interactions with few minimized steps for drug repurposing applications. Among molecular omics databases, we suggest CCLE [76] as it links drug omics with molecular omics and contain comprehensive data on 1457 cell lines, 84 434 genes, ∼1 million mutations and 400 million methylation scores. If someone is interested in interactive visualization of molecular and drug responses across cancer cell lines, then CellMiner CDB [83] could be a good choice. Among pathway databases, KEGG [85] is one of the most comprehensive and nonredundant database (0.6 million pathways). It contains pathways for >6000 species with this information linked to diseases and drug target interaction information, as shown in Table 2 . It is also the most cited among the pathway databases and contains some variant data. PDB [119] is one of the most comprehensive databases when it comes to protein 3D structures, with >140 K protein structures accessible via API.
Drug target interaction databases
Among bioactivity or drug target interactions databases, Pub-Chem [120] and ChEMBL [95] could be the databases of choice as these contain enormous nonredundant bioactivity datasets with more than 15 million curated bioactivities. Additionally, both have linked bioactivity data with several other datatypes, such as chemical structures and physiochemical properties, clinical data and disease indications. STITCH [107] and DTP [31] are good if someone is interested in drug target interaction visualization, as can be seen in Table 3 . DTP is based on curated bioactivates whereas STITCH combines bioactivities with predicted compound target interactions using a weighted mechanism.
Disease databases
OpenTargets [108] and DisGeNET [34] are the most comprehensive databases when it comes to protein and disease associations, both having information on >17K proteins and >10K diseases. DisGeNET, additionally, has associated protein variants with human diseases. If someone is specifically interested in cancer biomarkers, COSMIC [109] could be a good choice as it contains comprehensive and curated list of somatic mutations associated with different cancers, as shown in Table 4 . Clinical trials (https://clinicaltrials.gov/) is one of the most comprehensive clinical DBs, containing information on both failed and successful trials, as well as drug combinatorial studies for 0.3 million clinical studies. The problem with most of the clinical databases is that the data are not in structured format and are not downloadable in case of some databases (require manual copy/paste or web scrapping). Among the side effects databases, we suggest Sider [116] as it has a structured format that is easily downloadable and quite comprehensive (5868 side effects for 1430 drugs).
Examples of drug repositioning, database use, methods and limitations
In this section, to illustrate how databases can be used for drug repositioning, we provide examples of the prerequisites and methods of drug activity prediction and the databases that have been used. We also illustrate a few important issues that affect several types of data and influence both the primary drug development and repositioning efforts. For specific examples of drug repositioning other than the ones provided below, the reader is referred to the Drug Repurposing Portal (http://www. drugrepurposingportal.com/).
Drug repositioning is facilitated by molecular target annotation
Approval of small molecule compounds for new indications requires a sufficient degree of mechanistic insight, which in turn is dependent on identifying the drug binding partners at molecular level. Several endeavors are underway to catalogue comprehensive binding profiles of existing small molecules and cellular macromolecules [121] [122] [123] [124] . To facilitate drug-target annotation efforts, an open annotation and query platform called Drug Target Commons (DTC) [30] , which provides a summary of currently known molecular targets for thousands of drugs, has recently become available. Of all the molecular targets, kinase inhibitors are among the most studied as they function both as therapeutics and as molecular tools to examine cellular processes. Because of the conserved nature of the ATP binding pocket of the kinases, kinase inhibitors are more than likely to bind and inhibit several targets. This implies that repurposing of such inhibitors is a task requiring cataloguing affinities and assigning functional ranking to the targets. For example, Abl kinase-inhibitor imatinib has found use outside chronic myeloid leukaemia, as it also targets at least wild type c-Kit and PDGFR receptor tyrosine kinases within a well-tolerated clinical concentration range [125] . Another example of repurposing effort that relied on drug annotation information is the repurposing of SRC kinase inhibitor saracatinib. It was originally developed for several types of cancers but was abandoned due to poor efficacy. Later on, it was known to possess affinity toward FYN kinase and was proceeded to Phase II testing for Alzheimer's disease, in which FYN plays an important pathogenic role [126, 127] . While that 159 Alzheimer patient trial unfortunately did not show clinical benefits for saracatinib, brain imaging indicated that the drug may have influenced some pathological processes [126] , which possibly can support generation of new combination regimens for this devastating disease in the future. Other examples include anti-inflammatory asthma medication montelukast, which was found to bind dipeptidyl peptidase IV [128] , a promising drug target in type II diabetes. Diclofenac, simvastatin, ketoconazole and itraconazole, on the other hand, were found to bind to estrogen receptors, whereby they potentially could find uses in targeting estrogen-dependent cancers [128] .
In addition to knowing which targets small molecules can bind, it is important to know the mode of action (inhibitory/activating). For example, anti-helminthic agent pyrvinium binds to and activates CK1α kinase, which has a net inhibitory effect on the Sonic Hedgehog pathway by virtue of CK1α acting as an endogenous antagonist for this pathway [129] . However, even drugs with broad or only partially defined molecular target ranges can be repurposed. One such example is the famous drug disulfiram, also known as Antabuse, that has been used to treat alcohol abuse since 1948 because one of its metabolites inhibits aldehyde dehydrogenase (ALDH), generating discomfort upon alcohol consumption. However, it displays anti-cancer effects which are still incompletely understood and are at least independent of the ALDH-inhibitory function and associated with protein accumulation of nuclear protein NPL4 in a copperdependent fashion [130] .
Drug-induced cellular responses and conditional cell states can be matched to facilitate drug repositioning
Drug repositioning often begins from observations in large phenotypic screens, which can then be matched to underlying mutations and gene expression patterns. The National Cancer Institute cell line panel (NCI-60), the Cancer Cell Line Encyclopedia (CCLE) and the collaborative Genomics of Drug Sensitivity in Cancer (GDSC) databases constitute the largest collections of genomic and drug response data from different cancer types to date. The data in these databases can be accessed, explored and visualized using the highly useful CellminerCDB portal [83] . The databases offer drug response measurements, transcription levels and mutation data, where CCLE features a greater number of mutations in at least KRAS, PTEN, BRAF, NRAS and MSH6 than in the GDSC or NCI-60 databases due to greater sequencing depth. GDA [131] is similar to CellminerCDB in many aspects: to simplify the user experience, expression data from both NCI-60 and CCLE have been combined into a single data point for each gene as the data between these databases are highly concordant. Transcriptomic and drug response data in databases, such as GDA, CCLE and GDSC, can be correlated to reveal drug mechanisms. In one study, high gene expression levels of fatty acid desaturase 2 (FADS2) were identified as a common denominator among ∼19 000 basal transcript levels across 823 different human cancer cell lines responding to the poorly characterized anti-cancer agent ML239. Subsequently, the anti-cancer potency of ML239 was demonstrated to be reduced in the cells knocked out for FADS2 or simultaneously treated with FADS2 inhibitor [132, 133] .
Cell-intrinsic changes, including epigenetic modulation and mutations, and external factors, such as cell-cell contacts; stroma and matrix; soluble signalling mediators; pressure and oxygen tension; may influence cell, tissue and bodywide transcriptional landscapes. Some of the molecular alterations are conserved across patients, mutations, and specific conditions, and can be categorized as disease-or stateassociated/enriched (Table 2) [134, 135] , which is the basis for drug connectivity mapping. As an example, the gene expression alterations triggered by three candidate compounds, disulfiram (Antabuse), metropolol, a beta1-receptor blocker used to treat high blood pressure, and nonsteroidal anti-inflammatory agent sulindac, were observed to match the gene expression patterns enriched in the neurocognitive disorder Fragile X, as reported in NCBI GEO and in unpublished sources [136] . These agents improved cognitive performance as measured in Fmr1 KO2 mice, which serve as an animal model of Fragile X. However, in most cases, rapidly fluctuating and heterogeneous transcriptomes necessitate feature selection. This means filtering of only the most relevant genes for predictive modelling, or, conversely, eliminating irrelevant genes that might confound correlative drug response analyses [137] . A form of feature selection useful for bulk transcriptomic data is deconvolution, whereby diverse cellular background signals can be separated from the gene expression changes associated with and predicting drug responses. As an example, the gene expression signatures of coding mutations across a large number of different cell types, called core transcriptomes, were filtered out from the gene expression changes triggered by the drugs to reveal the drugspecific, tissue-independent effects [137] . In this study, after core transcriptome filtering, several novel AKT inhibitors or FOXO and AMPK activators were found, which were able to extend C. elegans nematode lifespan, similar to the known agents affecting these pathways. The approach offered a promising strategy to complement other deconvolution tools, such as CIBERSORT, ImmuCC and DeMixT, which will likely prove useful in repurposing drugs based on mixed transcriptomes [138] [139] [140] . Tissue-specific transcriptomes can be accessed via Genotype-Tissue Project (GTEx) [141] .
Computational tools and machine learning facilitate drug structure-guided target prediction and repositioning
Concomitant with experimental drug-target discovery efforts that provide quantitative molecular affinity data, computational tools are being built to predict/infer new molecular targets using orthogonal drug-target space deconvolution, where the molecular structures of both the drugs and targets help guide predictions [105, 142] . As an example of drug-target prediction based on molecular docking, antipsychotic agent thioridazine was found among 1500 FDA-approved compounds to possess anti-inflammatory activity by binding and inhibiting IKK, critical for the NF-κB pathway, which was also validated in experimental assays [143] . Similarly, virtual docking predicted inhibitory activity for five compounds from a collection of more than 1400 FDA-approved drugs against Pseudomonas aeruginosa quorumsensing (population-wide virulence) mechanisms, with antipsychotic agent pimozide displaying in vitro activity in inhibiting bacterial virulence gene expression [144] . A recent study introduced CDRscan, an algorithm that incorporates drug response assay data from GDSC, genomic data from CCLE and virtual docking based on structural fingerprints, including quantitative structure activity relationships (QSAR) information from Drug-Bank [145] . CDRscan predicted anti-cancer activity for 176 of 1385 approved nononcology drugs, with 27 compounds showing strong predicted efficacy for at least one of the 25 cancer types in at least 10% of the cell lines evaluated, and four agents being assigned predicted anticancer activity against more than 90% of all cancer types.
Incorporating more omics variables creates new in silico drug repositioning opportunities awaiting clinical translation
New algorithms display ever increasing accuracy to match observed drug response patterns when additional variables are incorporated, such as drug-protein-interactions and proteinprotein interactions (PPI). Addition of PPI data from STRING [72] generated a new method, termed HNMDRP, that outperformed several state-of-the-art machine learning-based methods in correctly correlating responses of the drugs with the underlying combined weighted scores, calculated using drug structural, target cell mutational, drug-protein and PPI data [147] . Crossdatabase deep learning models have been used to predict drug responses and drug synergies based on drug-induced transcriptional changes [148, 149] and KEGG-defined signaling pathways [150] . Yet another promising computational repurposing tool is Dr Insight, which uses correlations between various 'omics' and clinical data and drug responses to enrich for drug-disease and drug-target connections without the need to extract or limit feature sets, thus, outperforming other well established drug repurposing methods, such as CMap [41] , sscMap [151] and NFFinder [152, 153] . No experimental validations were conducted in these studies, which limits the possibilities to evaluate their translational potential, and while response predictions for several compounds outside the training sets matched published data, it is difficult to know how these new algorithms would perform on previously unpublished, poorly annotated molecules.
Machine learning can even be used for drug repositioning by identifying the drug-disease links from word combinations in published texts. In a recent example, drug candidates for psoriasis and other inflammatory conditions were extracted from Pubmed abstracts using several different machine learning algorithms, of which partial least squares discriminant analysis outperformed other well-known approaches, such as random forest and LASSO regression [154] . The gene expression signatures associated with cellular responses to the drug candidates matched transcriptomic signatures associated with psoriasis, and at least five of the 20 top candidate drugs proposed by the machine learning approach already had been observed to have ameliorating activity in psoriasis, as listed in CTD [155] , Drug-Bank [36] and Pharmacogenomics Knowledgebase. However, all hits were relatively promiscuous immunomodulators and could be expected to have at least some activity in psoriasis and in other immune-mediated diseases. This implies that text mining might work best to extend drug utility rather than offer entirely new or unexpected uses for existing compounds.
Incorporating clinical databases for drug repurposing
An important consideration for any new repositioning study is whether the repositioned drug(s) would display the expected phenotypic effects both in preclinical models and in real patients/subjects. In this regard, databases in which clinical drug responses and side effects have been collected (Table 4 ) may be particularly useful. Cheng et al. [156] provided an example of pharmacoepidemiologic multi-database drug repurposing by inferring to potential cardiovascular side effects for a set of compounds based on the cardiovascular side effects of other drugs annotated in the patient databases IBM Watson/Truven Health Analytics MarketScan and Optum Clinformatics, and sharing close protein-protein interaction networks with the drugs of interest. By this approach, hydroxychloroquine was observed to be associated with significantly reduced risk for coronary arterial disease, and experimental testing corroborated previously published data that the drug inhibited several risk-associated cellular processes, notably TLR7/9-and TNFα signaling. As another example, terazosin, a drug approved for the treatment of benign prostatic hyperplasia, and in rare cases hypertension, was found to enhance the activity of phosphoglycerate kinase 1 (PGK1), which promotes glycolysis and cellular ATP production, which in turn was shown to increase neuronal survival in animal models of Parkinson's disease [157] . This novel hypothetical use was validated by association in two clinical databases, Parkinson's Progression Markers Initiative database and Truven Health Analytics MarketScan, where terazosin was associated with reduced risk to develop Parkinson's disease, reduced disease progression and amelioration of select clinical symptoms in the diagnosed patients [157] .
Drug repurposing workflow
The previous examples showcase how multidimensional data stored in the databases can be mined for drug repositioning. In this final section, in order to help readers further understand how various databases could be combined to generate drug repurposing hypotheses, we outline one possible integrative workflow for drug repurposing. As an example, we have used Acute Myeloid Leukaemia (AML) as the disease of interest, but this can be applied to any disease.
We started by searching clinical databases for drugs approved for AML. A list of appropriate databases is given in Figure 2 ; however, we recommend ClinicialTrials.gov (shown in bold-face) for this purpose as it is the most comprehensive and accessible database for 0.3 million clinical studies. We name this list of approved drugs for AML as Drug A. The next step could be to find drugs that are significantly similar (e.g. Tanimoto similarity >0. 3) to Drug A in terms of 2D chemical structure. We recommend PubChem [96] here because it not only contains ∼9 million structures, but also provides computed fingerprints through API. We name this list Drug B. The next step is to correlate bioactivity data for Drug A with Drug B. A subset of Drug B that has significant correlation with Drug A is proceeded to the next step where we need to check side effects for ⊂Drug B using Sider database [116] . The next step is to search for primary targets for ⊂Drug B, which can be obtained from ChEMBL [95] or DTC [30] . After that, we need to see whether these protein targets are highly expressed in AML cell lines. This can be done by processing data from CCLE [76] , GDSC [44] or CellMinerCDB [83] . The subset of Drug B, whose primary targets were highly expressed in AML cell lines, can be the possible repurposing candidate for AML. The subset of Drug B can be further validated by experimentation.
Conclusions
In this review, we analysed 102 databases, which can directly or indirectly affect the designing of the computational pipelines for drug repositioning. We have provided some characteristics and statistics for the databases and assigned those into primarily 4 main and 17 subcategories based on the main strengths of the databases. We have also provided information on how some databases have integrated multiple datasets and suggested preferable databases for each subcategory (or data type). We have also highlighted some of the machine learning methods, which are using databases to train models in order to find new indications for approved drugs, and provided a computational workflow using listed databases, which can help researchers to setup novel drug repurposing pipelines.
In general, the main limitations of the machine learningbased drug repositioning efforts stem from data heterogeneity and overabundance of variables as compared to the number of samples. Fortunately, both database hosts and the research community as a whole are aware of the main hurdles, and several solutions are being developed to address these concerns [158] .
Taken together, the early examples of drug repositioning using database-driven in silico exploration herald an expanding wave of discoveries of increasing accuracy that can be matched by experimental evidence. Combining several technical and modelspecific improvement scans facilitates the identification of new uses for existing drugs, thus accelerating MoA establishment for new chemicals.
Key Points
• This manuscript provides a survey on available databases, which could directly or indirectly support drug repurposing. For the ease of understanding, the databases are divided into 4 main and 17 subcategories.
• In total, 102 databases are summarized, and the best databases are recommended for each subcategory based on data quality, comprehensiveness, data types and usage.
• The manuscript also sheds light on how databases can be used for drug repositioning and provides examples of the methods for drug activity prediction by using data from public databases.
• Finally, a systematic workflow for disease-based drug repurposing is provided showing the usage of given databases that can lead to assigning new applications for drug repurposing.
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